Angen.Is

ANGEN.IS has a market capitalization of 2.44 billion TRY and a price-to-book ratio of 1.41, indicating that the market values the company at a moderate premium to its book value. The company's liquidity position is characterized by a current ratio of 2.82, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's free cash flow is negative at -600.99 million TRY, and capital expenditures are substantial at -435.99 million TRY, indicating significant investment in long-term assets.

Profitability metrics show a challenging financial position for ANGEN.IS. The company reported a net loss of 312.73 million TRY and an operating loss of 19.21 million TRY, resulting in a return on equity of -18% and a return on assets of -13.23%. These figures are below the industry median for profitability, highlighting the company's struggle to generate returns for shareholders and asset holders.

ANGEN.IS's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification increases the company's exposure to market-specific risks, particularly in the healthcare diagnostics sector. The absence of segment or geographic breakdowns in the financial data limits the ability to assess the company's exposure to different markets or product lines.

Looking ahead, ANGEN.IS is expected to face continued financial pressure. The company's operating cash flow of 186.55 million TRY is insufficient to offset the negative free cash flow, and the capital expenditures suggest ongoing investment in infrastructure or R&D. The company's debt-to-equity ratio of 0.17 indicates a relatively conservative capital structure, but the negative net cash position after subtracting total debt raises concerns about liquidity.

The risk assessment for ANGEN.IS highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential challenges in maintaining liquidity without external financing. The dilution risk is low, as the number of shares outstanding remains unchanged between basic and diluted shares, suggesting no imminent threat from share issuance.

Recent financial filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The absence of recent events or disclosures limits the ability to assess the company's response to market conditions or regulatory changes.